If you have suffered a loss on your DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DCXM) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at [email protected], or fill out ...
Hosted on MSN
Should You Buy DexCom Stock Before Oct. 31?
Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...
Now, it’s worth noting Stock Advisor's total average return is 1,064% — a market-crushing outperformance compared to 194% for ...
Recently, multiple class action lawsuits were filed against DexCom, Inc. after reports surfaced alleging the company made unauthorized design changes to its G6 and G7 continuous glucose monitoring ...
The Case: Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Dexcom, Inc. securities during the class period because the Company ...
Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") filed a class action in the U.S. District Court for the Southern District of New York alleging violations ...
NEW YORK, NY - November 6, 2025 ( NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) on ...
DexCom, a leading manufacturer of continuous glucose monitoring systems, is confronting one of the most significant ...
DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.
Dexcom has issued a Class I recall for its G6 Android app due to crashes that could cause users to miss critical glucose ...
The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that securities class action lawsuits have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback